More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease

被引：1
|
作者：
Kakiuchi, Toshihiko [1 ]
Yoshiura, Masato [1 ]
机构：
[1] Saga Univ, Fac Med, Dept Pediat, 5-1-1 Nabeshima, Saga 8498501, Japan
来源：
DIGESTIVE AND LIVER DISEASE | 2023年 / 55卷 / 02期
关键词：
ULCERATIVE-COLITIS; REMISSION;
D O I：
10.1016/j.dld.2022.11.004
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：298 / 299
页数：2
相关论文
共 50 条
  • [31] Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study
    Ginard, Daniel
    Khorrami, Sam
    Perez-Carazo, Leticia
    Tavio-Hernandez, Eduardo
    Lopez-Sanroman, Antonio
    Garcia-Alvarado, Maria
    Munoz, Fernando
    Ibanez-Samaniego, Luis
    Marin-Jimenez, Ignacio
    Guevara, Jorge
    Casellas, Francesc
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (06): : 369 - 376
  • [32] Discussion on the biologic therapy of inflammatory bowel disease
    Merger, M
    Herfarth, H
    Scholmerich, J
    Andus, T
    Färber, L
    GASTROENTEROLOGY, 2003, 124 (07) : 2005 - 2006
  • [33] Biologic Therapy in Inflammatory Bowel Disease Preface
    Loftus, Edward V., Jr.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : XV - XVII
  • [34] Trends in choice of first line biologic therapy for patients with Inflammatory Bowel Disease. An observational cohort study
    Fernando, S.
    Abu-Rgeef, R.
    Menon, S.
    So, K.
    Venugopal, K.
    Picardo, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I307 - I308
  • [35] Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice
    Chaudrey, Khadija
    Lightner, Amy
    Singh, Siddharth
    Faubion, William
    Tremaine, William
    Bruining, David
    Papadakis, Konstantinos
    Kisiel, John
    CoelhoPrabhu, Nayantara
    Raffals, Laura
    Kane, Sunanda
    Loftus, Edward, Jr.
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S19 - S20
  • [36] Efficacy and Safety of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease
    Navaneethan, Udayakumar
    Kommaraju, Kiran Kumar
    Edminster, Timothy
    Zhu, Xiang
    Wilson, Kenneth
    Glover, Sarah C.
    GASTROENTEROLOGY, 2016, 150 (04) : S812 - S812
  • [37] Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome
    Thau, Eve
    Moore, Hillary Aaron
    Stein, Philip
    Chen, Kathy
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 68 (05): : E88 - E88
  • [38] COST-EFFECTIVENESS OF SEQUENCING VEDOLIZUMAB AS FIRST-LINE BIOLOGIC IN ULCERATIVE COLITIS AND CROHN'S DISEASE IN CANADA
    Fischer, A.
    Mac, S.
    Freiman, E.
    Marshall, J.
    Rand, K.
    Ramos-Goni, J. M.
    VALUE IN HEALTH, 2023, 26 (12) : S84 - S84
  • [39] ADALIMUMAB IS ASSOCIATED WITH DECREASED HEALTHCARE RESOURCE UTILIZATION, STEROID USE AND DISEASE COMPLICATIONS COMPARED TO VEDOLIZUMAB AS FIRST-LINE BIOLOGIC THERAPY IN CROHN'S DISEASE
    Ungaro, Ryan C.
    Griffith, Jenny
    Garcia-Horton, Viviana
    Cross, Raymond K.
    GASTROENTEROLOGY, 2021, 160 (06) : S3 - S4
  • [40] EFFICACY AND DURABILITY OF BIOLOGIC THERAPY AFTER FAILURE OF INITIAL AND SUBSEQUENT BIOLOGIC AGENTS IN INFLAMMATORY BOWEL DISEASE
    Cusumano, Vivy T.
    Ebriani, Joseph
    Prakash, Preeti
    Dua, Anoushka
    Fansiwala, Kush
    Spartz, Ellen
    Sauk, Jenny S.
    Limketkai, Berkeley N.
    GASTROENTEROLOGY, 2022, 162 (07) : S816 - S816
12345